Breast cancer online : BCO最新文献

{"title":"A case of thigh swelling in a patient with metastatic breast cancer receiving combination chemotherapy","authors":"A. Schott","doi":"10.1017/S1470903105004177","DOIUrl":"https://doi.org/10.1017/S1470903105004177","url":null,"abstract":"and significant tenderness on palpation. Doppler examination was negative for deep vein thrombosis (DVT), and X-ray showed no change in the known sclerotic femur lesion. Physical therapy for presumed lymphedema was initiated, along with analgesics, and her chemotherapy was continued. The pain and swelling worsened significantly over the subsequent 3 weeks and required escalation of the dose of narcotic anal-gesic, though these symptoms were noted by the patient to wax and wane without appreciable pattern. A magnetic resonance imaging (MRI) of the thigh was performed. This showed, consistent with the clinical examination, diffuse circumferential subcuta-neous edema, and skin thickening. The rectus muscle was diffusely swollen and edematous, with sur-rounding fluid. In addition, there was the impression of a 1.0 cm (cid:1) 3.5 cm mass in the muscle, demon-strating rim enhancement with central hypointensity, worrisome for necrotic metastasis or abscess. An ultrasound was done to rule out abscess and to aid in a tissue diagnosis. However, this revealed only","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105004177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated partial breast irradiation: 3-dimensional conformal external beam radiotherapy","authors":"Y. Hasan, F. Vicini","doi":"10.1017/S1470903105003639","DOIUrl":"https://doi.org/10.1017/S1470903105003639","url":null,"abstract":"The use of three-dimensional conformal external beam accelerated partial breast irradiation (3D conformal APBI) to deliver hypofractionated adjuvant radiation treatment to the region of the breast at highest risk for developing a local recurrence after lumpectomy is reviewed. Potential advantages of a 3D conformal radiation therapy approach for APBI compared to brachytherapy include improved dose homogeneity within the target volume and a non-invasive method for treatment delivery. Data from several early studies using 3D conformal APBI from New York University, William Beaumont Hospital, RTOG 0319, and Massachusetts General Hospital demonstrate technical feasibility, satisfactory early cosmetic outcome, and acceptable recurrence rates. To determine whether APBI provides equivalent local tumour control in the breast compared to conventional whole breast irradiation in the local management of early stage breast cancer, the first phase III randomized study of conventional whole breast irradiation vs. partial breast irradiation was opened conjointly by the NSABP and RTOG in March 2005. The results of this study will determine future directions in the treatment of early stage breast cancer, and, will help to define the role of APBI in breast conservation therapy.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105003639","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Mammotome excision of fibroadenomas","authors":"A. Maxwell","doi":"10.1017/S1470903105004852","DOIUrl":"https://doi.org/10.1017/S1470903105004852","url":null,"abstract":"Abstract Fibroadenomas are most common benign tumour of the breast, usually affecting pre-menopausalwomen. The traditional treatment aimed at symptomatic relief and confirmation of the lesion’s benign naturethrough open surgical excision and biopsy. The rise of ‘triple assessment’ in recent years has meant that adefinitive benign diagnosis is now generally possible without recourse to open biopsy. But patients would stillface undergoing open surgical excision for relief of symptoms. A third option is now available – that of percu-taneous vacuum-assisted excision under local anaesthetic. Performed in a similar fashion to conventional per-cutaneous needle biopsy, the procedure can normally be completed within 15min and offers quicker recoverytimes and better cosmetic outcome than traditional excision. Keywords: Benign breast tumours; Fibroadenomas; Mammotome; Percutaneous vacuum-assisted excision Focus On Correspondence to: Dr AJ Maxwell, Consultant Radiologist, Royal BoltonHospital. Tel: 01204 390387/010/397. E-mail: anothony.maxwell@rbh.nhs.ukReceived: 02/10/05Revised: 09/11/05Accepted: 10/11/05First published online 17/02/06BCO/485/2005/FO","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2006-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105004852","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of plasma membrane ER protein in breast cancer","authors":"E. Rosen, S. Fan, Y. Ma, E. Levin","doi":"10.1017/S1470903105003366","DOIUrl":"https://doi.org/10.1017/S1470903105003366","url":null,"abstract":"","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2006-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105003366","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of lesions first detected on MRI: what to do?","authors":"L. Bartella, E. Morris","doi":"10.1017/S1470903105004591","DOIUrl":"https://doi.org/10.1017/S1470903105004591","url":null,"abstract":"Breast magnetic resonance imaging (MRI) has been shown to date to be of value in the high-risk population. Challenges in interpretation are present. Maintaining a high volume of examinations in dedicated centers definitely impacts positively on experience in interpretation. MR-guided intervention is a necessity in all diagnostic centers where breast MRI is performed. Guidelines in interpretation should be used in conjunction with optimum technique and by combining kinetic and morphologic information with clinical history and conventional imaging (mammography and ultrasound) findings, a recommendation for management can be made with more assurance.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105004591","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New opportunities in premenopausal breast cancer: goserelin (‘Zoladex’) plus aromatase inhibition","authors":"R. Jakesz","doi":"10.1017/S1470903105004323","DOIUrl":"https://doi.org/10.1017/S1470903105004323","url":null,"abstract":"Results from trials demonstrating the superiority of the third-generation aromatase inhibitors (AIs; anastrozole, letrozole and exemestane) vs. tamoxifen have led to changes in clinical practice in the treatment of postmenopausal patients with hormone-sensitive breast cancer. AIs do not inhibit ovarian oestrogen synthesis sufficiently to be a viable monotherapy for premenopausal patients but there is interest in their potential use in combination with luteinising hormone-releasing hormone analogues (LHRHas) such as goserelin (‘Zoladex’). Preliminary results from Phase II combination trials in the advanced breast cancer setting have been promising, but efficacy data in premenopausal patients with early disease are yet to be reported. Here we overview the rationale and preliminary results to date for the combination of AIs with an LHRHa and highlight ongoing trials that will more fully assess the value of such combinations in extending the treatment options for premenopausal breast cancer patients.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105004323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of disseminated and circulating tumour cells in breast cancer","authors":"D. Auer, Alois Schneitter, C. Marth, S. Braun","doi":"10.1017/S1470903105002038","DOIUrl":"https://doi.org/10.1017/S1470903105002038","url":null,"abstract":"Occult dissemination of tumour cells in patients with operable breast cancer is a crucial step in formation of metastasis, yet conventional tumour staging does not reveal it. To identify individual tumour cells that have successfully escaped from the primary tumour and invaded secondary organs, several research groups established sensitive immunocytochemical and molecular assays. Aside of the well documented prognostic impact of lymph node metastasis and micrometastases, respectively, bone marrow plays a prominent role as a determinant for haematogenous micrometastatic organ involvement. In the past decade, several groups have documented the independent prognostic impact of the presence of bone marrow micrometastases, which, in a recent pooled analysis of individual patient data from over 4000 breast cancer patients with Stage I–III disease, could be confirmed for the entire study population, and, in addition, provided data for challenging hypotheses to be tested in future adjuvant therapy trials of clinically relevant subgroups of breast cancer patients. Although the availability of a simple blood test would be highly desirable, no prognostically relevant data so far exists for early breast cancer patients. Options for the applicability of such approaches to detect disseminated (to bone marrow) and circulating tumour cells (in blood) are ample, both in clinical trial settings and for basic as well as translational research. In this overview we provide a brief summary of the prognostic role and the potential clinical utility of bone marrow micrometastases in breast cancer patients.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105002038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shift in the surgical treatment of non-palpable breast cancer: tactile to visual","authors":"K. Dowlatshahi, J. Dieschbourg","doi":"10.1017/S1470903105003755","DOIUrl":"https://doi.org/10.1017/S1470903105003755","url":null,"abstract":"Increasing number of small, early-staged breast cancers are detected by screening mammography. Diagnosis and determination of the prognostic factors may be made by either ultrasound (US) or stereotactically guided needle biopsy. Approximately 2000 stereotactic tables are installed at various medical centers throughout the United States and a significant number in other countries where breast cancer is common. Many surgeons and interventional radiologists are trained in the use of this technology for diagnostic purposes. Employing the same technology, these physicians may be trained to treat selected breast cancers with laser energy percutaneously. Experimental and clinical reports to-date indicate the technique to be safe. High-resolution imaging modalities including grayscale and color Doppler US, magnetic resonance imaging, mammography and needle biopsy, when necessary, will confirm the tumor kill. Newer imaging modalities such as magnetic resonance spectroscopy may also provide additional confirmation for total tumor ablation.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2006-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903105003755","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56919363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A response to high-dose estrogen for tamoxifen, aromatase inhibitor and trastuzumab refractory HER2+ and ER+ advanced breast cancer","authors":"B. Nervi, A. Denes, M. Ellis","doi":"10.1017/S1470903106004159","DOIUrl":"https://doi.org/10.1017/S1470903106004159","url":null,"abstract":"A 66-year-old Caucasian woman without a significant past medical history underwent a routine bilateral mammography in October 2001 that showed a speculated mass in the right breast. Ultrasound examination of the right breast revealed two separate masses (1.7 and 1.4 cm) suggestive of malignancy. A core biopsy showed invasive ductal carcinoma, and the patient underwent a right lumpectomy with sentinel lymph node dissection that revealed two separated invasive carcinomas: 1.5 1.5 and 1.7 1.3 cm, poorly differentiated with signet ring features, extensive lymphovascular invasion, positive margins in one of the lesions, areas of in-situ lobular carcinoma, ER , PR , and HER2 with gene amplification by FISH (Ratio of 5.6 for HER2 amplification adjusted for chromosome 17 polysomy; ratio of greater of 2 indicates amplification). One of fifteen axillary lymph nodes was positive for carcinoma with a 0.2 cm metastatic implant. Subsequently the patient had a right modified mastectomy with TRAM reconstruction with no evidence of residual carcinoma in the breast, and one in two additional lymph nodes examined were positive for carcinoma. The tumor marker Ca 15-3 was elevated up to 85 units/ml (normal 32 units/ml). She was found on staging evaluation (computerized tomographical (CT) scan, bone scan) to have radiographic findings consistent with mixed lytic–sclerotic metastasis in the left proximal femur. Follow-up evaluation with positron emission tomographical (PET) scan confirmed intense increase in uptake of F-18 fluorodeoxy-glucose (FDG) within the left femoral intertrochanteric region, as well as a focus of increased activity in the right ischial region and the right iliac crest suspicious for bone metastasis. In summary, this is a post-menopausal patient who presented with Stage IV breast carcinoma with bone metastasis and increased tumor marker Ca 15-3. The tumor biomarkers suggested that the tumor was estrogen dependent but amplification of HER2 was also present. Besides a mild left hip pain, the patient was asymptomatic with a performance status ECOG 0.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106004159","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science (July 2005)","authors":"R. Sutherland, J. Scorer","doi":"10.1017/S1470903106004998","DOIUrl":"https://doi.org/10.1017/S1470903106004998","url":null,"abstract":"1. Altundag K, Altundag O, Morandi P, Ozcakar B, Boruban C. The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. Mol Cancer Ther 2005; 4: 1136. 2. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005; 23: 4687–4694. 3. Barry JB, Giguere V. Epidermal growth factorinduced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha. Cancer Res 2005; 65: 6120–6129. 4. Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005; 280: 24428–24434. 5. Boulay A, Rudloff J, Ye JJ, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen SU, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11: 5319–5328. 6. Buhler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 2005; 3: 365–371. 7. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factoralpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 2005; 146: 3113–3122. 8. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, Casavola V, Zaccolo M, Reshkin SJ. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell 2005; 16: 3117–3127. 9. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao WL, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122: 33–43. 10. Chen L, Madura F. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65: 5599–5606. 11. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSPand HGF-mediated signaling networks. Oncogene 2005; 24: 5053–5068. 12. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D’Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005; 11: 4741–4748. 13. De Se","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"9 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2006-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903106004998","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56920751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}